Chronic obstructive pulmonary disease
Conditions
Interventions
Control group:conventional treatment(advising patients to quit smoking using bronchodilators inhaling glucocorticoids using expectorants and providing oxygen therapy and non-invasive ventilation when
Trial group:Conventional treatment (advising patients to quit smoking using bronchodilators inhaling glucocorticoids using expectorants and providing oxygen therapy and non-invasive ventilation when n
Sponsors
Lanzhou Petrochemical General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: With reference to the 2021 revised guidelines for the diagnosis and management of COPD and the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) pulmonary function tests demonstrating persistent airflow limitation are necessary to confirm the diagnosis of COPD and the criteria for the presence of persistent airflow limitation are: FEV1/FVC <70% after inhalation of a bronchodilator.The diagnosis of COPD was based on a history of exposure to risk factors The diagnosis of COPD is based on a history of exposure to risk factors medical data such as symptoms signs and pulmonary function tests and the exclusion of other diseases that may produce similar symptoms and persistent airflow limitation and is determined by inductive analysis. (1) Patients who meet the above diagnostic criteria and are clinically diagnosed with stable COPD; (2) 18 to 85 years of age mentally alert and able to cooperate with this trial; (3) No relevant motor or neurological diseases; (4) Patients without drug allergy who can participate in this trial after evaluation by clinicians of relevant specialties; (5) Voluntary participation in research and signing of informed consent form;
Exclusion criteria
Exclusion criteria: (1)Pregnant or lactating women or other vulnerable populations; (2)Presence of mental disorders or cognitive impairments that preclude compliance with the study protocol; (3)Severe cardiac hepatic or renal dysfunction or other systemic diseases; (4)Current participation in other clinical trials; (5) History of malignant tumors or current diagnosis of malignancy;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary function indicators;Traditional Chinese Medicine Syndrome Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| mMRC Score;CAT Score;Vital signs;Number of acute exacerbations; | — |
Countries
China
Contacts
Public ContactCaihong Wei
Lanzhou Petrochemical General Hospital
Outcome results
None listed